Lupin has launched generic of Tamiflu Capsules, 30 mg, 45 mg, and 75 mg in the US market. The drug was approved on January 9, 2018, and the company has immediately launched it in the US market.Tamiflu (Oseltamivir Phosphate) is a Hoffman-La Roche, Inc’s drug which had annual sales of approximately USD 467.8 million in the US as per IMS data in October 2017.Oseltamivir Phosphate Capsules USP, 30 mg, 45 mg, and 75 mg had annual sales of approximately USD 467.8 million in the US. (IMS MAT October 2017).While this news is positive for Lupin, it is also negative for Natco Pharma and Cadila Healthcare who already have their gTamiflu version in the US market.
CapitalStars Award Winning , SEBI registered , ISO certified investment advisory company. We provide intraday & positional services in Equity , derivative ,commodity & currency. Our research is highly skilled & experienced .
Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
No comments:
Post a Comment